Media Advisory and Interview Opportunity: Movember Joins Forces with Jon Montgomery on a Moustache Mission for Men’s Health
01 nov. 2024 05h00 HE
|
Movember Canada
TORONTO, Nov. 01, 2024 (GLOBE NEWSWIRE) -- It’s Movember 1 and Canada’s hairiest campaign is back to raise awareness, education and important funds for men’s health. This year, Olympian and...
Préparez-vous au décollage : Movember s'associe à l'une des moustaches les plus reconnaissables du Canada pour s'attaquer à la santé masculine
01 oct. 2024 09h00 HE
|
Movember Canada
TORONTO, 01 oct. 2024 (GLOBE NEWSWIRE) -- Moustaches (Mos) sont de retour à l'occasion de la campagne la plus poilue du Canada, le 1er Novembre! Cette année, Movember est fier de s'associer à...
Get Ready for Liftoff: Movember Joins Forces with One of Canada’s Most Recognizable Moustaches to Take on Men’s Health
01 oct. 2024 09h00 HE
|
Movember Canada
TORONTO, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Moustaches (Mos) are back as Canada’s hairiest campaign returns on Movember 1! This year, Movember is proud to be partnering with Olympian and...
Provectus Biopharmaceuticals Announces Publication of Preclinical Data of Oral Administration of Provectus Rose Bengal for Solid Tumor Cancers
18 avr. 2024 08h00 HE
|
Provectus Biopharmaceuticals Inc.
Research on breast, colorectal, head and neck, and testicular cancersNovel downregulation of WNK1 and Wnt signaling KNOXVILLE, TN, April 18, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals,...
BioNTech präsentiert auf ESMO-Kongress weitere ermutigende Daten aus Phase-1/2-Studie mit CAR-T-Programm BNT211 in schwer zu behandelnden soliden Tumoren
09 sept. 2022 10h30 HE
|
BioNTech SE
Follow-up-Daten zeigen ermutigende Anzeichen für eine klinische Anti-Tumor-Aktivität sowie ein kontrollierbares Sicherheits- und Verträglichkeitsprofil; Daten bauen auf den positiven...
BioNTech Presents Encouraging Phase 1/2 Follow-up Data for CAR-T Candidate BNT211 in Hard-To-Treat Solid Tumors at ESMO
09 sept. 2022 10h30 HE
|
BioNTech SE
Follow-up data further demonstrate encouraging signs of clinical anti-tumor activity and a manageable safety and tolerability profile, building on the positive interim data presented at AACR in...
BioNTech erhält Priority-Medicines (PRIME)-Status der EMA für verstärkte regulatorische Unterstützung des CAR-T-Kandidaten BNT211 zur Behandlung von Hodenkrebs
23 juin 2022 11h00 HE
|
BioNTech SE
Erster BioNTech-Produktkandidat, der von der Europäischen Arzneimittelagentur den Priority-Medicines (PRIME)-Status erhält; dies ermöglicht eine verstärkte regulatorische Unterstützung bei der...
BioNTech Receives Priority Medicines (PRIME) Designation from EMA for Enhanced Regulatory Support of CAR-T Candidate BNT211 in Testicular Cancer
23 juin 2022 11h00 HE
|
BioNTech SE
First BioNTech product candidate to receive priority medicines (PRIME) designation by the European Medicines Agency for enhanced regulatory support facilitating the clinical development of the...
Provectus Biopharmaceuticals Announces Presentation of Multiple Protein Kinase Signaling Targets, including WNK1, for PV-10® Immunotherapy at American Association for Cancer Research (AACR) 2022 Annual Meeting
11 avr. 2022 07h30 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, April 11, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that preclinical research on systemic administration of investigational cancer immunotherapy PV-10 (rose...
Provectus Biopharmaceuticals Announces Publication of In Vitro Data from Research on Oral Delivery of PV-10® at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
09 juin 2021 07h00 HE
|
Provectus Biopharmaceuticals Inc.
— PV-10 treatment induced autophagic cell death in all breast, colorectal, head and neck, and testicular cancer cell lines tested — Represents prerequisite in vitro data for clinical testing...